Etiology of Dengue Fever

ABSTRACT

Since the 1950s, dengue fever has turned into a significant general wellbeing worry all over the planet. As indicated by the World Health Organization (WHO), 2.5 billion people have been presented to dengue fever and its ramifications. As indicated by a contemporary study, there are 390 million examples each year, with 96 million of those giving at minimum a few clinical manifestations. Cautioning signs were proposed as a pointer for dengue in 2009 by WHO. Patients with any warning signs ought to be conceded to a medical clinic for perception and therapy.

KEYWORDS

Platelets; Haemorrhagic; Anti-NS1 antibodies; Plasma leaking; Transfusions

INTRODUCTION

To focus on restricted assets, it is basic to examine DHF/DSS (Dengue Haemorrhagic Fever/Dengue Shock Syndrome) in the most solid, prudent, and opportune way [1]. Dengue is brought about by one of four flavivirus serotypes (DEN1, DEN2, DEN3, and DEN4) that are firmly related yet antigenically specific [2]. Since cross invulnerability isn’t given by contamination by one of these serotypes, individuals who live in a dengue endemic region can have up to four unmistakable dengue encounters [2,3]. DF is a self-restricted febrile ailment, DHF is set apart by coming up next side effects, unmistakable haemorrhagic signs related with thrombocytopenia and an expanded vascular porousness [4]. DHF is hard to analyse clinically, particularly in the beginning phases of the condition [5]. Thrombocytopenia and a rising haematocrit are normal outcomes in DHF cases by the third or fourth day of the infection [6]. Thrombocytopenia can happen in DF however dengue infection prompted bone marrow concealment and decreased levels of platelets [7].

Pathophysiology of Dengue Haemorrhagic Fever

Dengue results in low platelets and coagulopathy [8]. Low platelets are brought about by dengue infection causing thrombopoiesis concealment in the bone marrow or platelet annihilation by NS1 antibodies [9]. Platelet plays a crucial part in the treatment of dengue fever and interior mucosal draining is the main sign for platelet transfusion in dengue [10]. At the point when a patient’s platelet count falls under 10,000- 20,000/ul, both the patient and the specialist request platelet transfusion treatment [11]. Dengue infection produces haem concentrates by expanding narrow porousness and plasma spilling into extravascular space [12]. Red blood cells demonstrate whether a patient is affected severely or is going to go into dengue shock [13]. Platelet profile on the other hand demonstrate that platelet breakdown is ceaseless or regardless of whether the bone marrow is responsive [14].

Role of Red Cell Indices

Haematocrit (HCT) is most fundamental measure in identifying dengue entanglements [15]. HCT rise over standard shows hemoconcentration and perhaps unavoidable shock [16]. Plasma leakage from vessels which are additionally seen in dengue fever are the reason behind it [17].

Role of Reticulocyte Production Index

The reticulocyte production index (RPI) is believed to be a sensible proxy marker for anticipating bone marrow response [18]. The expansion in RPI and the increment in post dengue platelet count have a solid affiliation. Patients with a RPI over the cut-off (RPI>3) have a decent bone marrow regenerative capacity and their platelet count will ultimately rise [19].

Role of Mean Platelet Volume

Platelet enactment and pseudopod development cause an expansion in MPV in dengue [20]. Moreover, juvenile platelets are set free from the bone marrow, which are bigger in size and could be one more reason for raised MPV [21]. Mature platelets become greater and more dynamic when platelet production decreases, and MPV levels rise [22]. Expanded MPV related to a consistent platelet count might show heling, however industriously brought MPV up related to proceeded with thrombocytopenia might demonstrate dynamic sickness causing platelet obliteration and the requirement for platelet transfusion [23]. Patients with haemorrhagic propensities have lower MPV levels joined with serious thrombocytopenia (20,000 platelets/Ul) could be an admonition indication of dengue fever and sign the requirement for red cell transfusion [24].

EPIDEMOLOGY

Dengue fever is a significant disease affecting numerous tropical and sub-tropical nations, including Sri Lanka [25]. From January to October 2017, the Epidemiology Unit of Sri Lanka’s Ministry of Health detailed 165,517 speculated dengue cases, over two times the number recorded in 2016, when 55,150 cases were accounted for [26]. From January to October 2017, an aggregate of 403 dengue passings were accounted for [27]. In spite of expanded case occurrence, there has been a diminishing in dengue mortality over the past twenty years, demonstrating that in-ward the executives has improved with time [28]. Notwithstanding, since the most widely recognized coursing dengue serotype differs in the populace, the clinical example of dengue changes, and the case occurrence rises, more data and assets are required for both preventive and remedial parts of the sickness [29]. The Teaching Hospital Peradeniya, a tertiary consideration clinical office, treated generally 50% of the dengue patients in Kandy region [30]. From January to August 2017, 515 patients with positive dengue serology (positive NS1 or positive IgM and IgG) were admitted [31].

Haematological, Serological and Virological Analysis

The female bite of the Aedes aegypti mosquito, which is tainted with four serotypes of the infection, communicates the infection to people. In people, the viral hatching time frames from 3 to 15 days, with a normal of 5 days following transmission [32]. Thrombocytopenia and leukopenia are utilized as a prescient marker to help with the early recognition of dengue fever [33]. The platelet count is the main supplemental lab test open in the fringe regions that can help the determination of DHF or DSS, other from the dengue-explicit attributes [34]. Viral interpretation, record, and replication are completely helped by non-primary proteins [35]. NS1 is one of these proteins that plays a part in viral RNA replication. NS1 is novel in that it is communicated on the outer layer of infectious cells however doesn’t comprise part of the virion [36]. Discharged NS1 (sNS1) levels in the blood have been displayed to connect with infection titres and have been utilized to analyse dengue [37]. The recognition of IgM and IgG antibodies is utilized for dengue infection determination, with the IgM counter acting agent catch compound connected immunosorbent test (MACELISA) being the most often involved serological methodology for routine treatment of dengue infection diseases [38].

CONCLUSION

In order to prioritise limited resources, it is critical to analyse these WS capability in predicting who would likely develop to DHF/ DSS (Dengue Haemorrhagic Fever/Dengue Shock Syndrome) in the most reliable, economical, and timely manner.

REFERENCES

1. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clinical Microbiology Reviews 11(3): 480-496.
2. Guzman MG, Kouri G (2003) Dengue and dengue hemorrhagic fever in the Americas: Lessons and challenges. Journal of Clinical Virology 27(1): 1-13.
3. Siqueira JB, Martelli CMT, Coelho GE, Simplício AC, Hatch DL (2005) Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerging Infectious Diseases 11(1): 48-53.
4. Srichaikul T, Nimmannitya S (2000) Haematology in dengue and dengue haemorrhagic fever. Best Practice & Research Clinical Haematology 13(2): 261-276.
5. Sharma S, Sharma SK, Mohan A, Wadhwa J, Dar L, et al. (1998) Clinical Profile of Dengue Haemorrhagic Fever in Adults during 1996-Outbreak in Delhi, India. WHO 22: 20-30.
6. Leong KW, Srinivas P (1993) Corticosteroid-responsive prolonged thrombocytopenia following dengue haemorrhagic fever. Medical Journal of Malaysia 48(3): 369-372.
7. Srikiatkhachorn A (2009) Plasma leakage in dengue haemorrhagic fever. Thrombosis and Haemostasis 102(6): 1042-1049.
8. Sugianto NA (2021) Pathophysiology of dengue haemorrhagic fever. World Journal of Pharmaceutical Research 10(14): 218-223.
9. Chuansumrit A, Tangnararatchakit K (2006) Pathophysiology and management of dengue hemorrhagic fever. Transfusion Alternatives in Transfusion Medicine 8(1): 3-11.
10. Halstead SB (1993) Pathophysiology and pathogenesis of dengue haemorrhagic fever. Monograph on dengue dengue haemorrhagic fever, World Health Organization, New Delhi, India 80-103.
11. Schexneider KI, Reedy EA (2005) Thrombocytopenia in dengue fever. Current hematology reports, 4(2): 145-148.
12. Ramzan M, PrakashYadav S, Sachdeva A (2012) Post-dengue fever severe aplastic anemia: A rare association. Hematology oncology and stem cell therapy 5(2): 122-124.
13. Hendarto SK, Hadinegoro R (1992) Dengue encephalopathy. Acta Paediatrica Japonica 34(3): 350-357.
14. Ubol S, Masrinoul P, Chaijaruwanich J, Kalayanarooj S, Charoensirisuthikul T, et al. (2008) Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. The Journal of Infectious Diseases 197(10): 1459-1467.
15. Kantharaj A (2018) Role of red cell and platelet indices as a predictive tool for transfusions in dengue. Global Journal of Transfusion Medicine 3(2): 103-108.
16. Deshwal R, Qureshi MI, Singh R (2015) Clinical and laboratory profile of dengue fever. Journal of the Association of Physicians of India 63(12): 30-32.
17. Mukker P, Kiran S (2018) Platelet indices evaluation in patients with dengue fever. International Journal of Research Medical Sciences 6(6): 2054-2059.
18. Managoli N, Garg N, Raheja R, Jacob AJ, Atodaria K, et al. (2017) Limited role of platelet transfusion in dengue management and the value of reticulocyte production index as a measure of clinical improvement. International Journal of Scientific Study 4(12): 187-191.
19. Budianto R, Budiarti N (2019) Dengue hemorrhagic fever: Past, present and future. Berkala Kedokteran 15(1): 45-58.
20. Manoharan A, Sinha P (2017) Role of mean platelet volume in dengue fever-aprognostic marker. International Journal of Research and Review 4(6): 72-77.
21. Wiwanitkit V (2004) Mean platelet volume in the patients with dengue hemorrhagic fever. Platelets 15(3): 185-185.
22. Afsar N, Afroze IA, Humaira S, Abid Z (2017) Use of mean platelet volume as an initial diagnostic marker in evaluation of dengue fever. Annals of Pathology and Laboratory Medicine 4(3).
23. Kumar N, Swamy M, Chakraborti S, Kini J, Singh T, et al. (2018) Correlation of mean platelet volume and platelet distribution width in risk categories of dengue fever-a pilot study. Journal of Evolution Medical and Dental Sciences 7(2): 142-145.
24. Butkiewicz AM, Kemona H, Dymicka-Piekarska V, Matowicka-Karna J, Radziwon P, et al. (2006) Platelet count, mean platelet volume and thrombocytopoietic indices in healthy women and men. Thrombosis research 118(2): 199-204.
25. Messer WB, Vitarana UT, Sivananthan K, Elvtigala J, Preethimala LD, et al. (2002) Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. The American Journal of Tropical Medicine and Hygiene 66(6): 765-773.
26. Malavige GN, Jeewandara C, Ghouse A, Somathilake G, Tissera H (2021) Changing epidemiology of dengue in Sri Lanka-challenges for the future. Plos Neglected Tropical Diseases15(8).
27. Lanciotti RS, Lewis JG, Gubler DJ, Trent DW (1994) Molecular evolution and epidemiology of dengue-3 viruses. Journal of General Virology 75(1): 65-75.
28. Murray NEA, Quam MB, Wilder-Smith A (2013) Epidemiology of dengue: Past, present and future prospects. Clinical Epidemiology 5: 299-309.
29. Jelinek T (2009) Trends in the epidemiology of dengue fever and their relevance for importation to Europe. Eurosurveillance 14(25): 19250.
30. Ehelepola NDB, Ariyaratne K, Buddhadasa WMNP, Ratnayake S, Wickramasinghe M (2015) A study of the correlation between dengue and weather in Kandy City, Sri Lanka (2003-2012) and lessons learned. Infectious Diseases of Poverty 4(1): 1-15.
31. Kularatne SAM, Gihan MC, Weerasinghe SC, Gunasena S (2009) Concurrent outbreaks of Chikungunya and Dengue fever in Kandy, Sri Lanka, 2006-07: A comparative analysis of clinical and laboratory features. Postgraduate Medical Journal 85(1005): 342-346.
32. Kularatnam GAM, Jasinge E, Gunasena S, Samaranayake D, Senanayake MP, et al. (2019) Evaluation of biochemical and haematological changes in dengue fever and dengue hemorrhagic fever in Sri Lankan children: A prospective follow up study. BMC Pediatrics 19(1): 1-9.
33. Azin FRFG, Gonçalves RP, Pitombeira MHDS, Lima DM, Castelo BI (2012) Dengue: profile of hematological and biochemical dynamics. Revista Brasileira de Hematologia e Hemoterapia 34(1): 36-41.
34. Kain D, Jechel DA, Melvin RG, Jazuli F, Klowak M, et al. (2021) Hematologic parameters of acute dengue fever versus other febrile illnesses in ambulatory returned travelers. Current Infectious Disease Reports 23(12): 1-7.
35. Neupane B, Aryal GB, Lamichhane J, Pandey BD (2012) Clinical and hematological features of serologically confirmed dengue cases in Nepal. Journal of Biomolecular Reconstruction 9(2): 174-179.
36. Prasanna N, Punyashetty KB, Shankar AA, Tejeshwini P (2016) Clinicohematological profile in dengue-a tertiary care institutional study. National Editorial Board 6(1): 73.
37. Ahmed F, Ali ZAZ, Hussain Z (2014) Clinical and hematological profile of patients with dengue fever. Journal of Medical Sciences 22(1): 17-20.
38. Karyanti MR (2011) Clinical manifestations and hematological and serological findings in children with dengue infection. Paediatrica Indonesiana 51(3): 157-162.